Last year, despite the simultaneous adverse events, showed off the ability to overcome the crisis and won the 1st trillion club
[의학신문·일간보사=김영주 기자]Daewoong Pharmaceutical mentioned the tangible results of a new global blockbuster drug. Nabota has already proved its ability with the US FDA’s approval for sales and entry into the market. In particular, Daewoong Pharmaceutical is drawing more attention in that it raises expectations for rapid results due to the nature of Daewoong Pharmaceutical’s global advancement, which simultaneously proceeds with the new drug approval process and the floor for global advancement.
“The hot topic of Daewoong Pharmaceutical in 2021 is the rapid development and dissemination of COVID-19 treatments to restore the people’s daily lives along with the actual results of new drug development. In addition, we are determined to establish ourselves as a leading pharmaceutical company in the new year’s post-corona era.”
 |
Daewoong Pharmaceutical’s President Seung-ho Jeon (President Seung-ho Jeon), who has shown respectful leadership for 3 years in office, by achieving 1 trillion won even in difficult situations.Photo) Revealed the vision of Daewoong Pharmaceutical in 2021. I can feel the comfort and confidence of a company that has overcome simultaneous bad news.
He emphasized, “This year, Daewoong Pharmaceutical will be the year when the achievements of research and development cultivated so far will be realized in earnest.”
Analyzing Daewoong Pharmaceutical’s new drug development strategy, the short-term task is to enter large global markets such as the United States and China through the development of’Best-in-Class’ and implement blockbuster new drugs. First-in-Class)’ is interpreted as a long-term task and will continue to prepare one step at a time.
| Synthetic drug pipeline |
 |
The drugs that Daewoong Pharm is developing as the best new drug in the family are’Fexuprazan’, a gastroesophageal reflux disease treatment drug, and’Enavogliflozin’, a diabetes treatment drug.
Peksuprazan, a gastroesophageal reflux disease treatment drug based on the APA (P-CAB) mechanism, has completed an application for product approval with the Ministry of Food and Drug Safety as an indication for erosive gastroesophageal reflux disease. In phase 3 clinical trials in Korea, it was found to have a faster effect and excellent symptom improvement effect compared to existing drugs.
Currently, it has completed export contracts in Brazil and Mexico, and is in discussions with partners around the world to enter major global markets such as the United States, Europe, China, and Japan. In particular, it is planning to start clinical development in China this year by acquiring approval for Phase 1/3 of clinical trials in China in December of last year, and phase 3 clinical trials in the US are also being prepared.
President Jeon said, “The gastroesophageal reflux disease treatment market is a huge market with a scale of more than 40 trillion won worldwide, accounting for about 40% of the US and China.” It is expected to establish itself as a new blockbuster drug.”
Another best-in-class expected SGLT-2 inhibitor-based diabetes treatment’navogliflozin’ is a drug that has superior hypoglycemic effect and safety compared to existing drugs, and is currently undergoing phase 3 clinical trials in Korea smoothly.
Daewoong Pharmaceutical is undergoing phase 3 clinical trials on the use of Inabogliflozin alone, as well as metformin and metformin and DPP-4 inhibitors. In October of last year, it was designated as a drug subject to rapid review (Fast Track) by the Ministry of Food and Drug Safety for the first time in Korea. Currently, it is planning clinical trials to enter major global markets such as China and Japan, and is aiming to be released in Korea in 2023.
Daewoong Pharmaceutical currently has various pipelines for the world’s first innovative new drug. In particular, PRS fibrosis treatment (DWN12088), autoimmune disease treatment (DWP212525 · DWP213388), and stem cell treatment (DWP710) have very high growth potential.
The fibrosis treatment is currently being summarized in the results of phase 1 clinical trials conducted in Australia, and the autoimmune disease treatment system is aiming to enter the global phase 1 clinical trial this year. Stem cell therapy has confirmed its effectiveness against acute respiratory distress syndrome caused by COVID-19 infection and is completing phase 1 clinical trials in Indonesia.
“I think it is our mission as a pharmaceutical company to contribute to the health of the people through the development of treatments in critical situations such as the Corona 19 pandemic.”
President Seung-ho Jeon said about the background of the development of a treatment for Corona 19. Daewoong Pharmaceutical has the largest COVID-19 treatment pipeline among domestic pharmaceutical companies such as Hoy Star Tablet (Camostat), niclosamide injection, and stem cell treatment.
Among the COVID-19 treatments that Daewoong Pharm is developing, Hoy Star Tablet is developing the fastest. Hoista Tablet is a drug whose main ingredient is chamostat, and it inhibits the proliferation of viruses or the progression of inflammation through inhibition of entry into the cells, the first process by which the virus that has entered the human body enters and proliferates. In addition, unlike other drugs that act directly on the virus, it is a mechanism that inhibits the enzyme action of human cells, and it is predicted that it will be able to respond regardless of the virus mutation, which is a recent issue.
Daewoong Pharmaceutical confirmed the potential of Hoystar tablets to treat COVID-19 through the recently announced Phase 2a clinical topline results. It was confirmed that the virus removal rate of mild or asymptomatic confirmed patients hospitalized with Corona 19 tended to be faster than that of the placebo group, and the time it took for the patient’s clinical symptoms to improve was statistically significantly faster in the Hoystar group than in the placebo group.
At the same time, Daewoong Pharmaceutical is conducting phase 2b/3 clinical trials for mild patients, and recently, it has also received approval for phase 3 clinical trials for its preventive effect on self-isolation patients exposed to the Corona 19 virus.
On the other hand, Daewoong Pharmaceutical showed off its ability to overcome crises despite simultaneous adverse events last year, removing uncertainty in management. Daewoong Pharmaceutical has been on the list of 1 trillion clubs for 3 consecutive years since it achieved 1 trillion in sales for the first year in 2018 as President Seung-ho Jeon, the first year in history.
In addition to the business environment that has become difficult due to Corona 19, it is evaluated that it is more valuable because it has been achieved amid various crises such as Nabota lawsuits and measures to suspend Albis sales.
“Last year, Daewoong Pharmaceutical has faced the greatest difficulties since its inception, but Daewoong Pharmaceutical is overcoming the crisis with Daewoong-in’s unique strength, unity, and passion.”
Reporter Kim Young-joo [email protected]
<저작권자 © 의학신문, 무단 전재 및 재배포 금지>